Bibliographic record
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
- Authors
- Richard S. Finn, Shukui Qin, Masafumi Ikeda, Peter R. Galle, Michel Ducreux, Tae‐You Kim, Masatoshi Kudo, В. В. Бредер, Philippe Merle, Ahmed O. Kaseb, Daneng Li, Wendy Verret, Derek-Zhen Xu, Sairy Hernandez, Juan Liu, Chen Huang, Sohail Mulla, Yulei Wang, Ho Yeong Lim, Andrew X. Zhu, Ann‐Lii Cheng
- Publication year
- 2020
- OA status
- bronze
Print
Need access?
Ask circulation staff for physical copies or request digital delivery via Ask a Librarian.
Abstract
The combination of atezolizumab and bevacizumab showed encouraging antitumor activity and safety in a phase 1b trial involving patients with unresectable hepatocellular carcinoma.
Copies & availability
Realtime status across circulation, reserve, and Filipiniana sections.
Self-checkout (no login required)
- Enter your student ID, system ID, or full name directly in the table.
- Provide your identifier so we can match your patron record.
- Choose Self-checkout to send the request; circulation staff are notified instantly.
| Barcode | Location | Material type | Status | Action |
|---|---|---|---|---|
| No holdings recorded. | ||||
Digital files
Preview digitized copies when embargo permits.
- No digital files uploaded yet.
Links & eResources
Access licensed or open resources connected to this record.
- publisher Proxyable